According to AlphaMoat, in 2026-08 Orakl Oncology (orakl-oncology.com) received 2,122 monthly visits (-35.1% MoM) — ranked #15,077 of 17,407 AI websites with traffic data, and #2,663 of 3,173 in Industry Services; its largest market is United States (89.8% of visits).
What is Orakl Oncology
Orakl Oncology is an AI platform for oncology drug discovery that says it is building a native [AIxBio] engine: teaching AI to decode biology from its own datasets, predicting how disease evolves and how patients will respond to new drugs, to lower drug-development risk and open a new therapeutic era.
- 01The engine has three layers. The first is a living biology layer that scales patient-derived tumor organoids and screens them against drugs at large scale, each organoid a true likeness of its patient's tumor
- 02the second is the resulting signal-rich multimodal dataset covering paired drug response, clinical data, multi-omics, and medical imaging, said to be the largest of its kind in PDAC, CRC, and KRAS-mutant cancers
- 03the third is a prediction engine whose models the company says prospectively predict individual patients' response to new drug candidates with 90% accuracy across more than 30 clinical trials. The French legal page lists the site publisher as ORAKL Oncology, a simplified joint-stock company (SAS)
12-Month Traffic Trend
Visits by Country · Top 5
Popular in Industry Services
Data month: 2026-08 · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.